For patients whose cancers had outsmarted every other weapon
En los márgenes donde la medicina convencional había agotado sus respuestas, un ensayo internacional ha encontrado algo infrecuente: una vía de regreso. El fármaco Amivantamab, desarrollado por Johnson & Johnson y probado en 102 pacientes con cáncer de cabeza y cuello en 11 países, eliminó por completo los tumores en 15 personas y los redujo significativamente en 28 más, todas ellas resistentes a la quimioterapia y la inmunoterapia. Lo que el estudio OrigAMI-4 ofrece no es solo un dato clínico, sino una pregunta renovada sobre los límites de lo tratable.
- Pacientes que habían agotado todas las opciones convencionales —quimioterapia, inmunoterapia— vieron desaparecer sus tumores por completo, un resultado que los oncólogos califican de excepcionalmente sólido.
- La resistencia al tratamiento es uno de los mayores obstáculos en oncología, y este ensayo la desafía directamente en una población donde el pronóstico era sombrío.
- La administración subcutánea del fármaco —bajo la piel, no por vía intravenosa— reduce la carga del tratamiento y lo hace más compatible con la vida cotidiana de los pacientes.
- Carl Wash, de 56 años, pasó de no poder comer ni hablar con normalidad a recuperar esas capacidades tras diecisiete ciclos de tratamiento, ilustrando lo que los datos estadísticos no siempre capturan.
- Los resultados se presentarán ante la Sociedad Americana de Oncología Clínica este domingo, mientras el fármaco avanza en 60 estudios adicionales para cánceres de pulmón, colon, cerebro y estómago.
- El camino hacia la aprobación regulatoria y el acceso masivo sigue abierto e incierto, pero la dirección, por primera vez para muchos de estos pacientes, parece clara.
Un ensayo clínico multinacional ha arrojado resultados que la comunidad oncológica describe como inesperadamente contundentes. El estudio OrigAMI-4, desarrollado en 11 países con 102 pacientes de cáncer de cabeza y cuello, probó Amivantamab en personas cuya enfermedad había progresado o reaparecido tras fracasar los tratamientos estándar. Los resultados: desaparición completa del tumor en 15 pacientes y reducción significativa en otros 28.
El fármaco, creado por Johnson & Johnson, se administra mediante inyección subcutánea, lo que simplifica el tratamiento y reduce la dependencia hospitalaria. Los efectos secundarios registrados fueron leves o moderados, una ventaja notable frente a terapias que suelen dejar a los pacientes muy debilitados. Kevin Harrington, del Instituto de Investigación del Cáncer de Londres, subrayó que la fortaleza de estos resultados radica precisamente en el perfil de los pacientes: personas para quienes la medicina ya no tenía respuestas.
Entre ellos estaba Carl Wash, de 56 años, diagnosticado con cáncer de lengua en mayo de 2024. Cuando los tratamientos convencionales fallaron, se incorporó al ensayo. Tras diecisiete ciclos, la inflamación remitió, el dolor cedió y, seis meses después, pudo volver a comer con normalidad. Una recuperación que, para quien había perdido esa capacidad, tenía un peso que los números no reflejan del todo.
Amivantamab se encuentra ahora en fase de evaluación en 60 estudios adicionales, con foco principal en el cáncer de pulmón y extensión hacia tumores colorrectales, cerebrales y gástricos. Los resultados del OrigAMI-4 se presentarán este domingo en el congreso anual de la Sociedad Americana de Oncología Clínica en Chicago. Lo que sigue depende de si estos datos se consolidan, si se replican en otros tipos de cáncer y si los mecanismos regulatorios acompañan la urgencia de quienes esperan.
A multinational cancer trial has delivered results that oncologists are calling unexpectedly strong: a new vaccine called Amivantamab eliminated tumors entirely in 15 patients and shrank them significantly in 28 others. The OrigAMI-4 study, which spanned 11 countries and enrolled 102 patients with head and neck cancer, focused on people whose disease had spread or returned after other treatments failed. These are patients for whom options have largely run out—chemotherapy didn't work, immunotherapy didn't work. Yet when given this vaccine, developed by Johnson & Johnson, a meaningful portion experienced what amounts to a second chance.
The vaccine's mechanism is straightforward in concept but novel in execution. Amivantamab is delivered as a subcutaneous injection, which means patients receive it under the skin rather than intravenously. This practical detail matters more than it might sound: it makes treatment less burdensome, less tied to hospital visits, more compatible with ordinary life. The side effects reported in the trial were mild to moderate, a significant advantage over many cancer therapies that leave patients debilitated.
Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research in London, described the results as exceptionally strong precisely because of who received them. These patients had exhausted the standard arsenal. Their cancers had developed resistance to both chemotherapy and immunotherapy. For a treatment to work in this population—where hope is thin and options are thin—is, in Harrington's assessment, striking. He suggested the vaccine has potential to benefit thousands of patients annually.
One patient in the trial was Carl Wash, 56, who was diagnosed with tongue cancer in May 2024. Standard treatments failed him. He enrolled in OrigAMI-4 and found himself, by his own account, satisfied with the progress. By his seventeenth cycle of treatment, the swelling in his tongue had diminished. The pain that had made eating and speaking difficult began to ease. Six months into the trial, he could eat normally again—a small thing that, for someone whose disease had stolen that ability, was not small at all.
Amivantamab is not yet a finished story. The vaccine is currently being tested in 60 additional studies, most focused on lung cancer but also exploring its potential against colorectal, brain, and gastric tumors. Results from the OrigAMI-4 trial will be presented at the annual meeting of the American Society of Clinical Oncology in Chicago this coming Sunday. What happens next depends on whether these results hold, whether they extend to other cancer types, and whether regulatory pathways can move quickly enough to bring the treatment to patients who need it. For now, the trial has shown something that cancer research often struggles to show: a clear path forward for people who thought they had none.
Citações Notáveis
Results represent exceptionally strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy, a group with extremely limited treatment options.— Kevin Harrington, Institute of Cancer Research, London
Very satisfied with the progress so far, with swelling and pain in his tongue diminished and ability to eat restored after six months of treatment.— Carl Wash, trial participant with tongue cancer
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this is a subcutaneous injection rather than intravenous?
Because cancer treatment is not just about efficacy—it's about whether a person can actually sustain it. An IV infusion ties you to a clinic chair for hours. A shot under the skin takes minutes. Over months of treatment, that difference compounds. It's the difference between treatment being something that happens to you and something you can integrate into your life.
The trial focused specifically on patients who had already failed other treatments. Why highlight that?
Because it's the hardest test. If a drug works in newly diagnosed patients, that's valuable but expected. If it works in people whose cancers have already outsmarted chemotherapy and immunotherapy—that's when you know you've found something genuinely different. These are the patients with nowhere else to go.
Carl Wash could eat normally again after six months. Is that the main story here?
It's part of it. The complete tumor disappearance in 15 patients is the headline. But Wash's story is why the headline matters. He had a disease that took his ability to eat and speak. The vaccine gave it back. That's not a side benefit—that's the whole point of medicine.
What's the risk in presenting these results as hopeful?
The risk is that 87 of 102 patients didn't have complete tumor elimination. The vaccine worked significantly in 28 more, but 43 patients saw no major benefit. Hope is warranted, but it's not a cure-all. It's a tool that works for some people, in some circumstances, and we don't yet know why it works for some and not others.
Why are they testing it in 60 more studies?
Because head and neck cancer is just one type. If Amivantamab's mechanism works broadly, it could address lung cancer, colorectal cancer, brain tumors. Each cancer behaves differently, has different mutations, different vulnerabilities. The vaccine has to prove itself in each context separately.